SM
RCUS icon

SG3 Management’s Arcus Biosciences RCUS Stock Holding History

SG3 Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8,300
Closed -$172K – 142
2022
Q4 		$172K Buy
+8,300
New +$228K 0.02% 168
2022
Q2 		– Sell
-4,700
Closed -$148K – 741
2022
Q1 		$148K Buy
+4,700
New +$157K ﹤0.01% 805

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SG3 Management's RCUS Position: Q1 2023 in Review

SG3 Management sold out of Arcus Biosciences (RCUS) in Q1 2023, closing a stake of 5,000 shares — an estimated $103K sold.

SG3 Management first reported a position in RCUS in Q1 2022 and held it in 2 quarters. The position peaked at $158K in Q1 2022. 179 funds tracked by Wall St. Rank hold RCUS as of Q1 2023.

  • SG3 Management reported no remaining Arcus Biosciences position as of Q1 2023 after selling out during the quarter.
  • SG3 Management sold 5,000 Arcus Biosciences shares in Q1 2023, an estimated $103K.
  • SG3 Management first reported a position in Arcus Biosciences in Q1 2022 and held it in 2 quarters.
  • SG3 Management's Arcus Biosciences position peaked at $158K in Q1 2022.
  • 179 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2023.

Based on SG3 Management's 13F filing for Q1 2023, filed 15 May 2023.